GLAXOSMITHKLINE AND SEROXAT

Early day motion 2172, tabled 15 May 2006 by Paul Flynn (Labour). Signed by 40 members.

That this House condemns GlaxoSmithKline (GSK) for concealing for 15 years evidence that their anti-depressant drug Seroxat increases the risk of suicide and leads to `persistently worse' depression; congratulates the US Food and Drug Administration for forcing GSK to confess that users of Seroxat `experience emergent suicidality or symptoms that might be precursors to worsening depression or suicidality' and that `these symptoms may be severe and abrupt in onset'; and regrets the likely loss of life that has resulted from repeated denials of the lethal side effects of Seroxat by GSK, the Association of the British Pharmaceutical Industry and the Medicine and Healthcare Product Regulatory Agency in spite of the vigorous campaigns to reveal the truth by Professor David Healy, hon. Members, the Seroxat Users Group and Panorama.

Signatures by party: Labour 26, Liberal Democrat 9, Conservative 1, DUP 1, Plaid Cymru 1, Scottish National Party 1, Social Democratic and Labour Party 1.